Martti, our COO, has performed an analysis of some of the publicly available EV data to explore the value of local literature screening activity. The analysis is limited, but it does show some interesting data and point to what the reality and value of LLS is.

What we see as key figures from EudraVigilance 2020 Annual Report – a brief discussion on what picture this data paints about the industry and whether it needs a rethink on how we deal with the data volumes.

In this article, we have described general information about the COVID-19 vaccines that have been already approved or probably will be soon approved. We describe what kind of adverse events are to be expected for the vaccines and how often these appeared in the trials.

There was an opportunity to set an example and show commitment to innovation and necessary change – but on that, the strategy document falls short in most aspects.